Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85


The effect of tuberculosis treatment at combination antiretroviral therapy initiation on subsequent mortality: a systematic review and meta-analysis.

Soeters HM, Poole C, Patel MR, Van Rie A.

PLoS One. 2013 Oct 15;8(10):e78073. doi: 10.1371/journal.pone.0078073. eCollection 2013. Review.


The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review.

Soeters HM, Napravnik S, Patel MR, Eron JJ Jr, Van Rie A.

AIDS. 2014 Jan 14;28(2):245-55. doi: 10.1097/ Review.


The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.

Soeters HM, Sawry S, Moultrie H, Rie AV.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):136-44. doi: 10.1097/QAI.0000000000000284.


The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis.

Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RM.

PLoS One. 2014 Nov 12;9(11):e112017. doi: 10.1371/journal.pone.0112017. eCollection 2014. Review.


Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India.

Alvarez-Uria G, Pakam R, Midde M, Naik PK.

J Int AIDS Soc. 2014 Dec 9;17:19251. doi: 10.7448/IAS.17.1.19251. eCollection 2014.


Tuberculosis among HIV-infected patients in Stockholm, Sweden, 1987-2010: treatment outcomes and adverse reactions.

Wannheden C, Norrby M, Berggren I, Westling K.

Scand J Infect Dis. 2014 May;46(5):331-9. doi: 10.3109/00365548.2013.878033. Epub 2014 Feb 11.


Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.

Ku NS, Oh JO, Shin SY, Kim SB, Kim HW, Jeong SJ, Han SH, Song YG, Kim JM, Choi JY.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):226-30. doi: 10.1089/AID.2012.0192. Epub 2012 Sep 11.


Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.

Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M.

Cochrane Database Syst Rev. 2013 Oct 10;(10):CD010309. doi: 10.1002/14651858.CD010309.pub2. Review.


Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.

Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, Rutherford G, Mermin J.

AIDS. 2007 Mar 30;21(6):713-9.


Active tuberculosis is associated with worse clinical outcomes in HIV-infected African patients on antiretroviral therapy.

Siika AM, Yiannoutsos CT, Wools-Kaloustian KK, Musick BS, Mwangi AW, Diero LO, Kimaiyo SN, Tierney WM, Carter JE.

PLoS One. 2013;8(1):e53022. doi: 10.1371/journal.pone.0053022. Epub 2013 Jan 2.


Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy.

Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S.

J Infect. 2006 Dec;53(6):357-63. Epub 2006 Feb 17.


Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals.

Helleberg M, Kronborg G, Ullum H, Ryder LP, Obel N, Gerstoft J.

J Infect Dis. 2015 Jun 1;211(11):1726-34. doi: 10.1093/infdis/jiu669. Epub 2014 Dec 8.


Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review.

Link-Gelles R, Moultrie H, Sawry S, Murdoch D, Van Rie A.

Pediatr Infect Dis J. 2014 May;33(5):499-503. doi: 10.1097/INF.0000000000000142. Review.


Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.

Pac L, Horwitz MM, Namutebi AM, Auerbach BJ, Semeere A, Namulema T, Schwarz M, Bbosa R, Muruta A, Meya DB, Manabe YC.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):e69-76. doi: 10.1097/QAI.0000000000000527.


Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.

Thacher EG, Cavassini M, Audran R, Thierry AC, Bollaerts A, Cohen J, Demoitié MA, Ejigu D, Mettens P, Moris P, Ofori-Anyinam O, Spertini F.

AIDS. 2014 Jul 31;28(12):1769-81. doi: 10.1097/QAD.0000000000000343.


Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.

Uthman OA, Okwundu C, Gbenga K, Volmink J, Dowdy D, Zumla A, Nachega JB.

Ann Intern Med. 2015 Jul 7;163(1):32-9. doi: 10.7326/M14-2979. Review.


Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, Sonnerborg A, Aklillu E, Lindquist L.

PLoS One. 2015 May 12;10(5):e0122587. doi: 10.1371/journal.pone.0122587. eCollection 2015.


Early versus Delayed Antiretroviral Therapy for HIV and Tuberculosis Co-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Yan S, Chen L, Wu W, Fu Z, Zhang H, Li Z, Fu C, Mou J, Xue J, Hu Y.

PLoS One. 2015 May 22;10(5):e0127645. doi: 10.1371/journal.pone.0127645. eCollection 2015. Review.


Integration and task shifting for TB/HIV care and treatment in highly resource-scarce settings: one size may not fit all.

Van Rie A, Patel MR, Nana M, Vanden Driessche K, Tabala M, Yotebieng M, Behets F.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e110-7. doi: 10.1097/01.qai.0000434954.65620.f3.


Supplemental Content

Support Center